Beacon NSCLC-04

Study Overview

A one-page summary of the BEACON NSCLC-04 clinical trial.

What is this study?

BEACON NSCLC-04 is a multi-center, randomized, open-label Phase 2 clinical trial evaluating an investigational therapy for adults living with advanced non-small cell lung cancer (NSCLC). Study sites are located across the United States, United Kingdom, Germany, and Australia.

Who can take part?

We are enrolling adults aged 18 or older with a confirmed diagnosis of stage III or stage IV NSCLC who have completed at least one prior line of systemic therapy. The full eligibility criteria are reviewed with the study team at screening.

What will happen?

If you choose to take part, your study participation will last approximately 24 months. You will attend scheduled visits at a participating site for treatment, lab tests, imaging, and safety monitoring. All study-related care and study drug are provided at no cost to you.

Is taking part voluntary?

Yes. Taking part in a clinical trial is entirely voluntary. You may withdraw at any time, for any reason, and this decision will not affect the medical care you receive outside of the study.

How do I learn more?

Visit the Find a Site page on this website to connect with a participating study center, or speak with your care team. The full informed consent document will be reviewed with you before any study procedures begin.

This is a demonstration document for BEACON NSCLC-04. Sample content — not a substitute for the official study document reviewed with your care team.